文献速递肾血管病与高血压急性肾损伤慢性肾脏病

解剖显著动脉粥样硬化性肾血管病患者伴高危临床特征时血运重建的效应

The effect of revascularization in patients with anatomically significant atherosclerotic renovascular disease presenting with high-risk clinical features.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本研究基于1986–2014年单中心队列,分析血运重建对高危动脉粥样硬化性肾血管病患者死亡、进展至终末期肾病(ESKD)和心血管事件(CVE)的影响。中位随访58.4个月,结果显示在肾功能快速恶化患者中,血运重建与ESKD、CVE及复合事件风险降低相关;双侧≥70%肾动脉狭窄和基线蛋白尿<1 g/d的高危患者亦获益。

要点

  • 肾功能快速恶化者血运重建后ESKD风险HR 0.47(95%CI 0.25-0.85,P=0.01)。
  • 双侧≥70%肾动脉狭窄且高危者血运重建后肾脏与心血管结局更优。
  • 基线蛋白尿<1 g/d的高危患者血运重建后结局亦改善。

核心结论

  • 血运重建可能使解剖显著肾动脉狭窄且肾功能快速恶化的患者获益,尤其伴严重双侧病变或蛋白尿<1 g/d时。

研究设计与样本

  • 单中心队列研究,1986–2014年纳入经放射学诊断的动脉粥样硬化性肾血管病患者。

主要发现

  • 肾功能快速恶化患者血运重建后ESKD风险HR 0.47(95%CI 0.25-0.85,P=0.01)。
  • 肾功能快速恶化患者血运重建后CVE风险HR 0.51(95%CI 0.29-0.91,P=0.02)。
  • 肾功能快速恶化患者血运重建后复合事件风险HR 0.51(95%CI 0.29-0.90,P=0.02)。
  • 双侧≥70%肾动脉狭窄高危患者和基线蛋白尿<1 g/d患者血运重建后肾脏与心血管结局显著优于对照。

关键数值与推荐

  • 高危定义:≥70%单侧或双侧肾动脉狭窄,伴闪发性肺水肿、严重高血压或肾功能快速恶化之一。

临床怎么用

  • 对解剖显著肾动脉狭窄伴肾功能快速恶化者,可考虑血运重建,尤其存在双侧严重病变或蛋白尿<1 g/d时。

局限性

  • 单中心队列研究,非随机设计,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with atherosclerotic renovascular disease (ARVD) and high-risk clinical presentations have largely been excluded from randomized controlled trials comparing renal revascularization and optimal medical therapy. Here, we explore the effect of revascularization on death, progression to end-stage kidney disease (ESKD) and cardiovascular events (CVE) in a highly selected cohort of patients with ARVD. METHODS: All patients with a radiological diagnosis of ARVD referred to our tertiary centre have been recruited into a single-centre cohort study between 1986 and 2014. Patients with ≥70% unilateral or bilateral ARVD together with one or more of the following putative high-risk presentations were designated 'high-risk': flash pulmonary oedema (FPE), severe hypertension, rapidly deteriorating renal function. The effect of revascularization on clinical outcomes in high-risk patients, patients with bilateral severe ARVD and those with <1 g proteinuria at baseline was compared with 'control' patients who had the same degree of renal artery stenosis (RAS) but did not exhibit these features. RESULTS: Median follow-up was 58.4 months [interquartile range (IQR) 25.4-97.3]. Revascularization was associated with a reduced risk of progression to ESKD, CVE and all combined events in patients with rapidly deteriorating renal function [ESKD: hazard ratio (HR) 0.47 (95% confidence interval, CI, 0.25-0.85), P = 0.01; CVE: HR 0.51 (95% CI 0.29-0.91), P = 0.02; Any: HR 0.51 (95% CI 0.29-0.90), P = 0.02]. High-risk patients with bilateral ≥70% RAS and those with <1 g/day baseline proteinuria also had significantly better renal and cardiovascular outcomes post-revascularization when compared with controls. CONCLUSION: Our results indicate that revascularization may be of benefit in patients with anatomically significant RAS who present with rapidly deteriorating renal function, especially in the presence of severe bilateral ARVD or <1 g/day proteinuria.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Vassallo D, Ritchie J, Green D, et al. The effect of revascularization in patients with anatomically significant atherosclerotic renovascular disease presenting with high-risk clinical features. Nephrol Dial Transplant. 2018. PMID: 28371854. doi:10.1093/ndt/gfx025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。